| Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ... Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011 | 563 | 2011 |
| Complete RNA polymerase II elongation complex structure and its interactions with NTP and TFIIS H Kettenberger, KJ Armache, P Cramer Molecular cell 16 (6), 955-965, 2004 | 517 | 2004 |
| Structure of eukaryotic RNA polymerases P Cramer, KJ Armache, S Baumli, S Benkert, F Brueckner, C Buchen, ... Annu. Rev. Biophys. 37 (1), 337-352, 2008 | 473 | 2008 |
| Architecture of the RNA polymerase II-TFIIS complex and implications for mRNA cleavage H Kettenberger, KJ Armache, P Cramer Cell 114 (3), 347-357, 2003 | 442 | 2003 |
| Architecture of initiation-competent 12-subunit RNA polymerase II KJ Armache, H Kettenberger, P Cramer Proceedings of the National Academy of Sciences 100 (12), 6964-6968, 2003 | 361 | 2003 |
| Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies C Klein, C Sustmann, M Thomas, K Stubenrauch, R Croasdale, ... MAbs 4 (6), 653-663, 2012 | 284 | 2012 |
| Developability assessment during the selection of novel therapeutic antibodies A Jarasch, H Koll, JT Regula, M Bader, A Papadimitriou, H Kettenberger Journal of pharmaceutical sciences 104 (6), 1885-1898, 2015 | 265 | 2015 |
| Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics A Schoch, H Kettenberger, O Mundigl, G Winter, J Engert, J Heinrich, ... Proceedings of the National Academy of Sciences 112 (19), 5997-6002, 2015 | 201 | 2015 |
| Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions JF Sydow, F Lipsmeier, V Larraillet, M Hilger, B Mautz, M Mølhøj, ... PloS one 9 (6), e100736, 2014 | 184 | 2014 |
| Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry PF Jensen, V Larraillet, T Schlothauer, H Kettenberger, M Hilger, ... Molecular & Cellular Proteomics 14 (1), 148-161, 2015 | 101 | 2015 |
| Bispecific anti-VEGF/anti-ANG-2 antibodies M Baehner, U Brinkmann, G Georges, RA Griep, S Imhof-Jung, A Kavlie, ... US Patent 8,268,314, 2012 | 90 | 2012 |
| Structure of an RNA polymerase II–RNA inhibitor complex elucidates transcription regulation by noncoding RNAs H Kettenberger, A Eisenführ, F Brueckner, M Theis, M Famulok, P Cramer Nature structural & molecular biology 13 (1), 44-48, 2006 | 89 | 2006 |
| Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys K Stubenrauch, U Wessels, JT Regula, H Kettenberger, J Schleypen, ... Drug Metabolism and Disposition 38 (1), 84-91, 2010 | 71 | 2010 |
| Structure–function studies of the RNA polymerase II elongation complex F Brueckner, KJ Armache, A Cheung, GE Damsma, H Kettenberger, ... Acta Crystallographica Section D: Biological Crystallography 65 (2), 112-120, 2009 | 70 | 2009 |
| Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis TE Kraft, WF Richter, T Emrich, A Knaupp, M Schuster, A Wolfert, ... MAbs 12 (1), 1683432, 2020 | 57 | 2020 |
| Ocular half-life of intravitreal biologics in humans and other species: meta-analysis and model-based prediction A Caruso, M Füth, R Alvarez-Sánchez, S Belli, C Diack, KF Maass, ... Molecular Pharmaceutics 17 (2), 695-709, 2019 | 51 | 2019 |
| Bispecific, bivalent anti-vegf/anti-ang-2 antibodies M Baehner, S Imhof-Jung, A Kavlie, H Kettenberger, C Klein, J Thomas, ... US Patent 8,945,552, 2015 | 50 | 2015 |
| Assessing developability early in the discovery process for novel biologics ML Fernández-Quintero, A Ljungars, F Waibl, V Greiff, JT Andersen, ... MAbs 15 (1), 2171248, 2023 | 43 | 2023 |
| A simple strategy for preparation of sensor arrays: Molecularly structured monolayers as recognition elements T Hirsch, H Kettenberger, OS Wolfbeis, VM Mirsky Chemical communications, 432-433, 2003 | 43 | 2003 |
| Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain S Fenn, CB Schiller, JJ Griese, H Duerr, S Imhof-Jung, C Gassner, ... PLoS One 8 (4), e61953, 2013 | 42 | 2013 |
